Table 1 Clinical data in different cohort
Characteristics | Training and internal validation Cohort (n = 117) | External validation cohort (n = 33) | Prospective validation cohort (n = 30) | |||
|---|---|---|---|---|---|---|
cholangiocyte phenotype (-) (N = 77) | cholangiocyte phenotype (+) (N = 40) | cholangiocyte phenotype (-) (N = 21) | cholangiocyte phenotype (+) (N = 12) | cholangiocyte phenotype (-) (N = 21) | cholangiocyte phenotype (+) (N = 9) | |
Sex | ||||||
 Female | 7 (9.1%) | 4 (10.0%) | 1 (4.8%) | 1 (8.3%) | 3 (14.3%) | 1 (11.1%) |
 Male | 70 (90.9%) | 36 (90.0%) | 20 (95.2%) | 11 (91.7%) | 18 (85.7%) | 8 (88.9%) |
Age | ||||||
 Mean ± SD | 57.3 ± 10.2 | 55.4 ± 11.1 | 50.7 ± 8.08 | 50.8 ± 12.6 | 61.2 ± 14.6 | 59.3 ± 12.2 |
Hepatitis | ||||||
 Absent | 12 (15.6%) | 6 (15.0%) | 3 (14.3%) | 2 (16.7%) | 4 (19.0%) | 3 (33.3%) |
 Present | 65 (84.4%) | 34 (85.0%) | 18 (85.7%) | 10 (83.3%) | 17 (81.0%) | 6 (66.7%) |
AFP (ug/L) | ||||||
 ≤ 20 | 45 (58.4%) | 12 (30.0%) | 12 (57.1%) | 4 (33.3%) | 13 (61.9%) | 3 (33.3%) |
 > 20 | 32 (41.6%) | 28 (70.0%) | 9 (42.9%) | 8 (66.7%) | 8 (38.1%) | 6 (66.7%) |
ALT (U/L) | ||||||
 Median (Min, Max) | 31.0 (10.0, 241) | 37.0 (14.0, 241) | 34.0 (10.0, 259) | 34.0 (19.0, 241) | 26.0 (8.00, 134) | 24.0 (8.00, 237) |
AST (U/L) | ||||||
 Median (Min, Max) | 36.0 (14.0, 169) | 41.0 (18.0, 287) | 36.0 (14.0, 202) | 43.0 (21.0, 287) | 33.0 (21.0, 73.0) | 44.0 (21.0, 181) |
GGT (U/L) | ||||||
 Median (Min, Max) | 49.0 (12.0, 1060) | 85.0 (13.0, 735) | 71.0 (20.0, 611) | 92.5 (21.0, 735) | 65.0 (16.0, 366) | 50.0 (31.0, 449) |
NLR | ||||||
 Median (Min, Max) | 1.87 (0.480, 7.30) | 2.62 (0.74, 14.3) | 2.00 (1.12, 5.42) | 3.65 (0.740, 14.3) | 2.77 (1.03, 49.7) | 2.30 (1.49, 9.57) |
PLR | ||||||
 Median (Min, Max) | 103 (44.7, 251) | 120 (31.7, 1650) | 105 (60.7, 236) | 130 (47.8, 1650) | 96.2 (64.8, 222) | 111 (49.1, 228) |
Child-Pugh | ||||||
 A | 66 (85.7%) | 33 (82.5%) | 17 (81.0%) | 9 (75.0%) | 20 (95.2%) | 6 (66.7%) |
 B | 11 (14.3%) | 7 (17.5%) | 4 (19.0%) | 3 (25.0%) | 1 (4.8%) | 3 (33.3%) |
Modus operandi | ||||||
 Non-anatomic | 33 | 14 | 9 | 3 | 9 | 3 |
 Anatomic | 44 | 26 | 12 | 9 | 12 | 6 |